Navigation Links
Mersana Therapeutics Reports Phase I Results for XMT-1001 in Patients with Solid Tumors at AACR-NCI-EORTC International Conference
Date:10/24/2007

ximum tolerated dose (MTD) has not been reached and the study continues to accrue patients.

"Our Fleximer nanotechnology platform is designed to create proprietary new drugs from existing and novel pharmaceutical compounds," said Julie Olson, President and Chief Executive Officer of Mersana. "We are pleased to note that in the Phase I study, our proprietary Fleximer-controlled drug release system achieved results consistent with our objective of extending the half-life of the camptothecin analog while avoiding safety concerns. The favorable pharmacokinetic and safety data are consistent with results from preclinical studies of XMT-1001," she concluded.

About XMT-1001

XMT-1001 is Mersana's most advanced Fleximer(TM)-based product candidate. It utilizes a novel, dual release mechanism to liberate a camptothecin prodrug, which is then converted within cells into camptothecin, a DNA topoisomerase I inhibitor. In preclinical studies, XMT-1001 was better tolerated and more efficacious than either camptothecin or irinotecan in models of human cancer, showing extended plasma half-life and high concentrations in tumor tissue.

About Fleximer

Mersana is transforming oncology product development by creating new drugs from anti-cancer agents through application of its Fleximer nanotechnology platform. Fleximer is a novel, biodegradable and bio-inert polymer that can be chemically linked to drugs, including small chemical entities, peptides and biologics. Fleximer-based compounds can be individually designed to improve the therapeutic performance of drugs by modulating such properties as circulation time and site of release, while significantly improving toxicity profiles.

About Mersana Therapeutics, Inc.

Mersana, a privately held, venture backed company, utilizes its proprietary nanotechnology platform to transform existing and experimental anti-cancer agents into new, patentable drugs with superior pharmaceutical properties. The key com
'/>"/>

SOURCE Mersana Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
6. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
9. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., CANOGAPARK,Calif.,Nov.25/PRNewswire/--Praxi...sintheAmericanAcademyofFamilyPhysicians,(AAFP)Fami...rveyforimprovingmedicalquality,healthmaintenance,a...egislation.Praxisalsoranked#1amongdoctorsindicatin...y.Finally,Praxisalsorankednumberoneinthecountryinp...
(Date:11/25/2009)..., PHILADELPHIA,Nov.25/PRNewswire-FirstCall/--...cKelvey,theCompany,sPresidentandCEO,andKeithSchnec...duledtopresentatthe21stAnnualPiperJaffrayHealthCar...y,NewYork. ,, Interestedpartiesmayaccessthepres...ttp://www.ert.com .Thewebcastmayalsobeaccessedat h...
(Date:11/25/2009)..., COLLEGEPARK,Md.,Nov.25/PRNewswire-USNewswir...avingcream-likefoamthatstopsseverebleeding,wonfirs...goryoftheGlobalSecurityChallenge2009,companyoffici...riesfromaroundtheworld,Remedium,steampitchedtheiri...ondonSchoolofBusiness. ,, Remedium( www.remediu...
Breaking Medicine Technology:Praxis EMR Wins Top Rankings in 2009 AAFP EHR User Satisfaction Survey 2ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3Council for American Medical Innovation and The Aspen Institute Bring Leaders Together In Washington D C To Discuss The Economic Impact Of Medical 47756 1Council for American Medical Innovation and The Aspen Institute Bring Leaders Together In Washington D C To Discuss The Economic Impact Of Medical 47756 2WellStar Health System Deploys 11 000 Users on SuccessFactors in the Enterprise Cloud for Increased Employee Retention and Improved Business Results 47752 1WellStar Health System Deploys 11 000 Users on SuccessFactors in the Enterprise Cloud for Increased Employee Retention and Improved Business Results 47752 2WellStar Health System Deploys 11 000 Users on SuccessFactors in the Enterprise Cloud for Increased Employee Retention and Improved Business Results 47752 32009 Pharma ChemOutsourcing Show Attendance Up an Astounding 60 25 Despite Current Recession 12440 12009 Pharma ChemOutsourcing Show Attendance Up an Astounding 60 25 Despite Current Recession 12440 2
...ceuticals,Inc. (Nasdaq: ANDS ) presented a late-b...tional Conference on Antiviral Research (ICAR) in ...a on ANA598, a non-nucleoside,inhibitor of the hep...tation reported several preclinical attributes of ...ombination of the product candidate,with several o...
...ny,s Phase 3 Study for Wet AMD after ...lif., April 17 NeoVista, Inc. announced,today tha...granted the,company,s request to expand the number...al from 10 to 30 in the United States. The approve...ted with BEta RadiatioN,Epiretinal Therapy) trial,...
Other Medicine Technology:Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research 2Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research 3FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S. 2FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S. 3
(Date:11/26/2009)...Dental (RTDental), a leading dental group practice...pansion of its services to include LUMINEERS by a ... , Durham, NC (PRWEB) -- ...at Dr. Doug Macmillan, an experienced LUMINEERS ... training seminar. RTDental’s ability to fu...
(Date:11/25/2009)...wire/--WhenmostpeopleheartheacronymTMJ,theythinkof...ehelptheyneed.TMJstandsfortheTemporal-MandibularJo...withyourskull(temporalbone). ,, Themostcommonsy...ng,clickingorpoppingofthejaw.Butmanyothersymptomsc...tigue,sleepdisturbances,irritability,alossinfocus,...
(Date:11/25/2009)...-SentinelleMedicalInc.,aleadingmanufacturerofMagne...ScientificInc.,aleadingproviderofsoftwareenablingt...east4DAdvancedVisualizationsoftware. ,, Thisinn...ientbasedmedicalimagingofferinginthemarket.Calgary...rintaccess-requiringnosoftwaredownload,andrunsonan...
(Date:11/25/2009)...SNewswire/--AnarticlebyJanetWoodcock,M.D.,director...d"ADifficultBalance-PainManagement,DrugSafety,andt...JournalofMedicine. ,, (Logo: http://www.newscom...ticle,WoodcockdiscussesFDAeffortstostrikeabalanceb...nagingtherisksposedbyvariousanalgesics.Asexamples,...
(Date:11/25/2009)...,andPressJoinEfforttoEducate ,, MEMPHIS,Tenn.,...alBipolarFoundationandtheMedicAlertFoundationrecei...am,whichisnowbeingwidelyacceptedasapreventivehealt...polarFoundationreceivedaproclamationofendorsementv...uisianaMitchLandrieu.TheNationalBipolarFoundations...
Breaking Medicine News(10 mins):Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3
...N, Feb. 18 One year ago today, the,American peopl...ilitary,hospitals and outpatient facilities treati...istan. Amid the national outrage sparked by those,...y of Defense Don Rumsfeld, saying "the fruits of R...
...entists Converge in Chicago, CHICAGO, Feb. 18 Th...Society:,, Who: The Chicago Dental Society (CDS) ...s such as their own dental habits, adults seeking,...dental products in North America, here are a few o...
...ed reminders to participants, and they worked out ...ealthDay News) -- Specially programmed personal di...aged and older Americans to increase their physica...y information handouts or a PDA loaded with a prog...
...S, N.M., Feb. 18 Meat & Livestock Australia,(MLA)...hniques for,high-speed CT scans of livestock carca... known as FlashCT, IMTEC will begin Phase 1 of a,m...t for fat and bone content, marbling and other qua...
...Calif., Feb. 18 Nationally recognized,bariatric s...n Solano,County., A native Californian and third ...rgraduate degree from the University of California...edical,director for Bariatric Services at Baptist ...
...Kan., Feb. 18 Pain Relief Network,a national orga...atic abuse,of patients in pain, will be holding a ...deral Courthouse where they have filed papers aski...rary/WOD/WPS16-Schneider/PrnVsKansas-Complet ,e.zi...
Other Medicine News:Health News:Walter Reed Anniversary Exposes More McCain Double Talk 2Health News:Walter Reed Anniversary Exposes More McCain Double Talk 3Health News:Dentists' Top Five Oral Health Care Tips During Pregnancy 2Health News:Portable Computer Devices Can Aid Exercise Programs 2Health News:IMTEC to Become Technology Solutions Provider for Meat & Livestock Australia 2Health News:Veteran Bariatric Surgeon Expands Services to Solano County 2Health News:Pain Relief Network Sues to Halt Government Actions Taken Against Kansas Patients 2
Lipid Control Level 3
Lipid Control Level 1
Lipoprotein (a) Calibrator Series
Valproic Acid
Medicine Products: